{"id":7025707,"date":"2026-08-03T21:11:07","date_gmt":"2026-08-03T21:11:07","guid":{"rendered":"https:\/\/peraltafinancing.com\/uncategorized\/cerevasc-expands-manufacturing-with-wilmington-facility-for-eshunt-system\/"},"modified":"2026-08-03T21:11:07","modified_gmt":"2026-08-03T21:11:07","slug":"cerevasc-expands-manufacturing-with-wilmington-facility-for-eshunt-system","status":"publish","type":"post","link":"https:\/\/fivemor.com\/?p=7025707","title":{"rendered":"CereVasc expands manufacturing with Wilmington facility for eShunt System"},"content":{"rendered":"


\n<\/p>\n

\n
\n
\n \"\"\/\n <\/picture>
The eShunt system is undergoing investigation as a minimally invasive alternative to conventional shunt surgery for communicating hydrocephalus, including NPH. Credit: MAD.vertise \/ Shutterstock.com.<\/figcaption><\/figure>\n<\/p><\/div>\n

CereVasc has opened a new manufacturing and research facility in Wilmington, Massachusetts, US, as the company prepares for potential commercialisation of its investigational eShunt System.<\/p>\n

The move follows two recent milestones: the completion of patient enrolment in the pivotal STRIDE clinical trial and the close of an $85m Series C funding round.<\/p>\n

\n
\n
\"\"\/<\/figure>\n

Discover B2B Marketing That Performs <\/h4>\n

\n\t\t\t\t\t\tCombine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.\n\t\t\t\t\t<\/p>\n


\n\t\t\t\t\t\t\tFind out more <\/svg><\/span><\/a><\/p>\n<\/section>\n<\/div>\n

Located near Boston, the facility is intended to support assembly, inspection, testing, and manufacturing activities for the eShunt system.<\/p>\n

The device is undergoing investigation as a minimally invasive alternative to conventional shunt surgery for communicating hydrocephalus, including normal pressure hydrocephalus (NPH).<\/p>\n

CereVasc\u2019s new site is designed to accommodate anticipated commercial and operational requirements, including workforce growth.<\/p>\n

The company\u2019s employment expansion is supported by a tax incentive from the Massachusetts Life Sciences Center, linked to job creation in the region.<\/p>\n

CereVasc chairman and CEO Dan Levangie said: \u201cThis facility is an investment in CereVasc\u2019s future.<\/p>\n

\u201cIt expands the capabilities we\u2019ll need as we prepare for potential commercialisation of the eShunt system, supports our long-term growth and helps position us to bring this innovation to patients.<\/p>\n

\u201cWe\u2019re proud to continue building CereVasc in Massachusetts, where the life sciences community continues to fuel innovation.\u201d<\/p>\n

The STRIDE clinical trial is intended to form the basis of the company\u2019s expected Premarket Approval submission to the US Food and Drug Administration (FDA).<\/p>\n

The eShunt system uses a percutaneous transvenous-transdural approach and includes an endovascular, implantable cerebrospinal fluid shunt with delivery components.<\/p>\n

The device remains investigational and has not been approved by regulators in the US or elsewhere; its safety and effectiveness have not yet been established.<\/p>\n

In June 2026, CereVasc concluded patient enrolment<\/a> in its STRIDE pivotal study, assessing the safety and effectiveness of the investigational eShunt System for normal pressure hydrocephalus (NPH).<\/p>\n

<\/p>\n

<\/p>\n

\n